Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.

Bezard E, Brotchie JM, Gross CE.

Nat Rev Neurosci. 2001 Aug;2(8):577-88. Review.

PMID:
11484001
2.

Pathophysiology of the basal ganglia in Parkinson's disease.

Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW.

Trends Neurosci. 2000 Oct;23(10 Suppl):S8-19. Review.

PMID:
11052215
3.

[Pathophysiology and therapy of L-Dopa-induced dyskinesia].

Hadj Tahar A, Bézard E, Grondin R, Gross CE, Bédard PJ.

Rev Neurol (Paris). 2003 Dec;159(12):1125-42. Review. French.

PMID:
14978413
4.

[Understanding and treating levodopa-induced dyskinesias].

Hadj Tahar A, Bédard PJ.

Tunis Med. 1998 Dec;76(12):437-47. Review. French. No abstract available.

PMID:
10093483
5.

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E.

Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S25-9. Review.

PMID:
15885624
6.

New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.

Hadj Tahar A, Grondin R, Grégoire L, Calon F, Di Paolo T, Bédard PJ.

Adv Neurol. 2003;91:51-64. Review. No abstract available.

PMID:
12442663
7.

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

Fox SH, Chuang R, Brotchie JM.

Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Review.

PMID:
18772047
8.

Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.

Encarnacion EV, Hauser RA.

Eur Neurol. 2008;60(2):57-66. doi: 10.1159/000131893. Epub 2008 May 15. Review.

9.

L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.

Cenci MA.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S263-7. doi: 10.1016/S1353-8020(08)70014-2. Review.

PMID:
18267248
10.

Motor fluctuations and dyskinesia in Parkinson's disease.

Nutt JG.

Parkinsonism Relat Disord. 2001 Oct;8(2):101-8. Review.

PMID:
11489675
11.

Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.

Cheshire PA, Williams DR.

J Clin Neurosci. 2012 Mar;19(3):343-8. doi: 10.1016/j.jocn.2011.09.008. Epub 2012 Jan 16. Review.

PMID:
22249009
12.

Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.

Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW.

Ann Neurol. 2000 Apr;47(4 Suppl 1):S22-32; discussion S32-4. Review.

PMID:
10762129
13.

Should levodopa be used anymore?

Zegers de Beyl D.

Acta Neurol Belg. 2002 Dec;102(4):163-6. Review.

PMID:
12534242
14.
15.

Molecular mechanisms of L-DOPA-induced dyskinesia.

Jenner P.

Nat Rev Neurosci. 2008 Sep;9(9):665-77. doi: 10.1038/nrn2471. Review.

PMID:
18714325
16.

Advances in understanding L-DOPA-induced dyskinesia.

Cenci MA, Lindgren HS.

Curr Opin Neurobiol. 2007 Dec;17(6):665-71. doi: 10.1016/j.conb.2008.01.004. Epub 2008 Mar 4. Review.

PMID:
18308560
17.

Nondopaminergic mechanisms in levodopa-induced dyskinesia.

Brotchie JM.

Mov Disord. 2005 Aug;20(8):919-31. Review.

PMID:
16007614
18.

[Levodopa for Parkinson's disease: What have we learned?].

Juri C C, Chaná C P.

Rev Med Chil. 2006 Jul;134(7):893-901. Epub 2006 Aug 29. Review. Spanish.

19.

The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.

Brotchie JM.

Ann Neurol. 2000 Apr;47(4 Suppl 1):S105-12; discussion S112-4. Review.

PMID:
10762137
20.

[Physiopathology of the dyskinesias induced by L-dopa].

Grandas F, López-Ariztegui N.

Rev Neurol. 1997 Aug;25 Suppl 2:S151-6. Review. Spanish.

PMID:
9280682

Supplemental Content

Support Center